Pharmacokinetics, tissue distribution and excretion study of resveratrol and its prodrug 3,5,4′-tri-O-acetylresveratrol in rats

被引：82

作者：

Liang, Li ^{[1
]}

Liu, Xueying ^{[1
]}

Wang, Qingwei ^{[2
]}

Cheng, Sikun ^{[1
]}

Zhang, Shengyong ^{[1
]}

Zhang, Meng ^{[3
]}

机构：

[1] Fourth Mil Med Univ, Sch Pharm, Dept Med Chem & Pharmaceut Anal, Xian 710032, Peoples R China

[2] Fourth Mil Med Univ, Affiliated Hosp 2, Dept Pharm, Xian 710032, Peoples R China

[3] Fourth Mil Med Univ, Inst Mat Med, Sch Pharm, Xian 710032, Peoples R China

来源：

PHYTOMEDICINE | 2013年 / 20卷 / 06期

基金：

中国国家自然科学基金;

关键词：

3,5,4 '-Tri-O-acetylresveratrol; Resveratrol; Pharmacokinetics; Tissue distribution; Excretion; HPLC; TRANS-RESVERATROL; METABOLISM;

D O I：

10.1016/j.phymed.2012.12.012

中图分类号：

Q94 [植物学];

学科分类号：

071001 ;

摘要：

3,5,4'-Tri-O-acetylresveratrol (TARES) synthesized by acetylating three hydroxyl groups of resveratrol (RES) is a prodrug of RES. The aim of this study was to investigate and compare the pharmacokinetics, tissue distribution and excretion of TARES and RES in rats following a single intragastric gavage (i.g.) administration. After RES is transformed into TARES, its pharmacokinetic properties are improved, such as the t(1/2) has been prolonged and the AUC has been enhanced. And TARES follows linear plasma pharmacokinetics across the investigated dosage range in rats (77.5-310 mg/kg). The major distribution tissues of TARES or RES in rats were liver, spleen, heart and lung. TARES can increase the content of RES in lung significantly. There was no long-term accumulation of RES in rat tissues. Whether we administrated to rats of equimolar TARES or RES, total recoveries of RES in urine and feces within 36 h were low (0.99% or 0.07% in urine and 1.69% or 0.15% in feces). (C) 2012 Elsevier GmbH. All rights reserved.

引用

页码：558 / 563

页数：6

共 15 条

[1] Resveratrol: Preventing properties against vascular alterations and ageing [J].

Delmas, D ;

Jannin, B ;

Latruffe, N .

MOLECULAR NUTRITION & FOOD RESEARCH, 2005, 49 (05) :377-395

[2] Unique properties of polyphenol stilbenes in the brain:: More than direct antioxidant actions;: Gene/protein regulatory activity [J].

Doré, S .

NEUROSIGNALS, 2005, 14 (1-2) :61-70

[3] Resveratrol, a remarkable inhibitor of ribonucleotide reductase [J].

Fontecave, M ;

Lepoivre, M ;

Elleingand, E ;

Gerez, C ;

Guittet, O .

FEBS LETTERS, 1998, 421 (03) :277-279

[4] Biological activity of acetylated phenolic compounds [J].

Fragopoulou, Elizabeth ;

Nomikos, Tzortzis ;

Karantonis, Haralabos C. ;

Apostolakis, Constantinos ;

Pliakis, Emmanuel ;

Samiotaki, Martina ;

Panayotou, George ;

Antonopoulou, Smaragdi .

JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2007, 55 (01) :80-89

[5] Resveratrol and chemoprevention [J].

Goswami, Shyamal K. ;

Das, Dipak K. .

CANCER LETTERS, 2009, 284 (01) :1-6

[6] CORRECTION [J].

HILL, RW .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1978, 73 (362) :455-455

[7] Cancer chemopreventive activity of resveratrol, a natural product derived from grapes [J].

Jang, MS ;

Cai, EN ;

Udeani, GO ;

Slowing, KV ;

Thomas, CF ;

Beecher, CWW ;

Fong, HHS ;

Farnsworth, NR ;

Kinghorn, AD ;

Mehta, RG ;

Moon, RC ;

Pezzuto, JM .

SCIENCE, 1997, 275 (5297) :218-220

[8] The Use of 3,5,4′-Tri-O-acetylresveratrol as a Potential Prodrug for Resveratrol Protects Mice from γ-Irradiation-Induced Death [J].

Koide, Kazunori ;

Osman, Sami ;

Garner, Amanda L. ;

Song, Fengling ;

Dixon, Tracy ;

Greenberger, Joel S. ;

Epperly, Michael W. .

ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (04) :270-274

[9] Human hepatic cell uptake of resveratrol:: involvement of both passive diffusion and carrier-mediated process [J].

Lançon, A ;

Delmas, D ;

Osman, H ;

Thénot, JP ;

Jannin, B ;

Latruffe, N .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 316 (04) :1132-1137

[10] ALCOHOLIC BEVERAGES AND CORONARY HEART-DISEASE [J].

NANJI, AA ;

FRENCH, SW .

ATHEROSCLEROSIS, 1986, 60 (02) :197-198

← 1 2 →